REVB (Revelation Biosciences) חוב לטווח קצר להון

The market dynamics of Revelation Biosciences (REVB) reflected in the quotes on GURU.Markets show a debt-to-equity ratio of 0.02. The immune therapy developer integrates ESG principles and bioethics into its scientific research, reducing harmful emissions. The implementation of automated cytokine analysis systems optimizes personnel costs. The expected completion of primary tests for new drugs will serve as a growth driver, despite current R&D expenses.

For Revelation Biosciences (REVB), which is scaling clinical trials for immunomodulators, the short-term debt-to-equity ratio reflects the current dependence of operational activities on quick loans. This metric correlates liabilities with a maturity of up to one year against total equity, allowing investors to assess liquidity risk and balance sheet resilience to market shocks while awaiting molecular data.